.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Daiichi Sankyo
McKesson
Mallinckrodt
Merck
Argus Health
Johnson and Johnson
Baxter
Teva
Julphar

Generated: September 22, 2017

DrugPatentWatch Database Preview

Telavancin hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for telavancin hydrochloride and what is the scope of telavancin hydrochloride patent protection?

Telavancin hydrochloride
is the generic ingredient in one branded drug marketed by Theravance Biopharma and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Telavancin hydrochloride has one hundred and eighteen patent family members in thirty-five countries.

Two suppliers are listed for this compound.

Summary for Generic Name: telavancin hydrochloride

Tradenames:1
Patents:11
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list8
Clinical Trials: see list2,289
Patent Applications: see list3
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:telavancin hydrochloride at DailyMed

Pharmacology for Ingredient: telavancin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: telavancin hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,067,483Pharmaceutical compositions containing a gycopeptide antibiotic and a cyclodextrin► Subscribe
7,074,760Polyacid glycopeptide derivatives► Subscribe
8,541,375Glycopeptide phosphonate derivatives► Subscribe
8,003,755Hydrochloride salts of a glycopeptide phosphonate derivative► Subscribe
6,831,150 Reductive alkylation process► Subscribe
6,828,299 Polyhydroxy glycopeptide derivatives► Subscribe
7,157,554Glycopeptide carboxy-saccharide derivatives► Subscribe
6,770,621 Polyacid glycopeptide derivatives► Subscribe
7,265,086Glycopeptide carboxy-saccharide derivatives► Subscribe
7,026,288Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: telavancin hydrochloride

Country Document Number Estimated Expiration
European Patent Office1292612► Subscribe
China100532392► Subscribe
Australia2001261107► Subscribe
Ukraine75083► Subscribe
China1871253► Subscribe
Czech Republic303672► Subscribe
SloveniaEP2495251► Subscribe
Argentina035333► Subscribe
South Africa200209419► Subscribe
Japan2003531869► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TELAVANCIN HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0051France► SubscribePRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
00507Netherlands► SubscribePRODUCT NAME: TELAVANCINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, INCLUSIEF TELAVANCINE HYDROCLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001 - 002 20110902
2012002,C1292612Lithuania► SubscribePRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
/2011Austria► SubscribePRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
908Luxembourg► Subscribe91908, EXPIRES: 20260501
7Finland► Subscribe
C/GB11/056United Kingdom► SubscribePRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906
2011100062Germany► SubscribePRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
2011 00033Denmark► Subscribe
2012002Lithuania► SubscribePRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Medtronic
McKesson
McKinsey
Boehringer Ingelheim
Federal Trade Commission
Novartis
Colorcon
Baxter
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot